![Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA](https://www.seventure.fr/wp-content/uploads/2020/07/10_104270789-322x211.jpg)
5 October 2021
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase...